SymBiosis Capital Partners
BENTONVILLE, ARfiles as SymBiosis Capital Partners, LLC
$53m in 6 US stocks at the end of 31 March 2026. The top 10 are 100.0% of the money. It changed about 59.8% of the portfolio this quarter.
Value
$53m
Stocks
6
Top 10 share
100.0%
Turnover
59.8%
What changed this quarter
New
Bought for the first time this quarter.
- Wave Life SciencesWVE10.3% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- InventivaIVA24.8% of the fund-9%
- Rani Therapeutics HoldingsRANI5.1% of the fund-42%
- CleneCLNN4.0% of the fund-44%
Sold out
Sold their entire stake.
- VerastemVSTM-100%
- AmpliTech GroupAMPG-100%
- PrecigenPGEN-100%
- Nuvation BioNUVB-100%
- Aardvark TherapeuticsAARD-100%
- Generation BIO-100%
Holdings
- Surrozen
- Share
- <0.1%
- Value
- $2,400
- Shares
- 150,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| EvommuneEVMN | 55.8% | $29m | 1,280,778 | Held |
| InventivaIVA | 24.8% | $13m | 2,354,000 | -9% |
| Wave Life SciencesWVE | 10.3% | $5m | 750,000 | New |
| Rani Therapeutics HoldingsRANI | 5.1% | $3m | 3,667,585 | -42% |
| CleneCLNN | 4.0% | $2m | 431,094 | -44% |
| Surrozen | <0.1% | $2,400 | 150,000 | Held |
Over time and by industry
Value over time
Mar '26
Value is down 51.8% since 31 December 2025.
Where the money is
Health care100.0%
Other0.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.